Join us for a unique evening panel discussion
with three distinguished Harvard speakers
on
"From innovation to financing in medical research:
The latest developments from a Researcher, Banker and Philanthropist”
The latest developments from a Researcher, Banker and Philanthropist”
DATE: Tuesday, May 24, 2011
TIME: 7:00 PM - 9:00 PM
PLACE: France-Ameriques. 9-11 Ave. Franklin Roosevelt. 75008 Paris.
COST: €15 Members (HCF, HBS, Yale & FA), €25 Non-Members , €30 Late
RSVP HERE
TIME: 7:00 PM - 9:00 PM
PLACE: France-Ameriques. 9-11 Ave. Franklin Roosevelt. 75008 Paris.
COST: €15 Members (HCF, HBS, Yale & FA), €25 Non-Members , €30 Late
RSVP HERE
MORE INFO: The landscape of medical research funding and investment is dramatically changing. Factors include the financial downturn, US healthcare reform, emerging global markets, and the accelerating pace of technological advances. A visiting Harvard medical professor, a London-based M&A banker and a research foundation director will discuss the new competitive vs. collaborative models for stimulating innovation in the medical sector in the US and in Europe.
This event will bring a unique insight of the interactions between ideas and money in the highly competitive health sector.
Prof. Roland Baron of Harvard Medical School will discuss the latest R&D strategies of the big pharmaceutical corporations and the limits of the US model of close relationships between academia and industry;
David Tancredi (HMS) of the Fondation Leducq and Broadview Ventures, Inc., will explain the role of venture philanthropy to accelerate the translation of scientific discoveries into medical benefits;
Julien Fouter (HBS) of Deutsche Bank will discuss the latest Merger & Acquisition trends in the health sector.
The event will conclude with a short Q&A session and friendly drinks party giving the audience an unique opportunity to further interact with the panelists.
------------------------------------------------------------------------------------------------------------------------------
- Dr. Baron is internationally known for his groundbreaking advances in bone biology. His research is the basis for the development of novel therapies to prevent bone loss such as that in arthritis and osteoporosis.
From 1975 to 2008, Dr. Baron began a long career at Yale University where held several positions at Yale and became a tenured full professor.
In 2002 he founded ProSkelia, a small pharmaceutical company devoted to the discovery and development of new drugs for bone and hormonal dependent diseases. . Between 1994 and 2002, he also held the position of vice president and head of the Bone Diseases Group at Hoechst Marion Roussel and then Aventis.
Since 2008, Prof Baron chairs the Department Head and Professor of Oral Medicine, Infection, and Immunity at Harvard Medical School. He is also the chief editor of Bone, the Official Journal of the International Bone and Mineral Society.
- David Tancredi is a graduate of Harvard Medical School. David is currently the Scientific Director and member of the Board of Directors of the Fondation Leducq (www.flcq.org), France. Grants from the Fondation Leducq provide up to $6,000,000 over five years to European-North American research teams pursuing collaborative work in cardiovascular and neurovascular disease. The Fondation is also associated with Broadview Ventures Inc., a venture philanthropy firm whose mission is to accelerate the development of promising technology through targeted investment in early stage ventures.
- Julien Fouter is Head of EMEA Healthcare M&A at Deutsche Bank. He joined Deutsche Bank in 2005 after spending seven years at Merrill Lynch in M&A. Julien graduated from ESCP Europe and holds an MBA from Harvard Business School.
He was actively involved in recent healthcare transactions, advising Advent International on its acquisition of Priory Group (UK mental healthcare specialist and care homes operator), and Shire on its public-to-private acquisition of Movetis (Belgian biotech focused on the gastrointestinal therapeutic area).
Julien has an extensive track record in M&A advisory, including involvements in landmark transactions such as Pernord Ricard's acquisition of V&S, InBev's acquisition of Anheuser-Busch and Schneider's acquisition of Areva Transmission & Distribution jointly with Alstom.
